Screener
BridgeBio Pharma BBIO Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | Total | Level 1 | Level 2 | Level 3 |
|---|---|---|---|---|
| Total cash equivalents | 378,537 | 343,613 | 34,924 | — |
| Marketable securities: | ||||
| U.S. Treasury securities | 38,789 | — | 38,789 | — |
| Agency discount notes | 3,460 | — | 3,460 | — |
| Total marketable securities | 42,249 | — | 42,249 | — |
| Total financial assets | $420,786 | $343,613 | $77,173 | — |
| Liability | ||||
| Embedded derivative (included in “Deferred royalty obligations, net”) | $15,709 | — | — | $15,709 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's cash, cash equivalents, and marketable securities?
- BridgeBio Pharma (BBIO) reported cash, cash equivalents, and marketable securities of $42.25M in Q2 2026.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.
Ask your AI about BridgeBio Pharma's cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude